Deucravacitinib in PG

Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis

NCT07012057 ·Status: WITHDRAWN ·Phase: PHASE2

Glasdegib for Chronic Graft-Versus-Host Disease

NCT04111497 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

NCT06136403 ·Status: RECRUITING ·Phase: PHASE2

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

NCT05221320 ·Status: TERMINATED ·Phase: PHASE2

An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

NCT03137160 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)

NCT04750213 ·Status: COMPLETED

Use of KC706 for the Treatment of Pemphigus Vulgaris

NCT00606749 ·Status: COMPLETED ·Phase: PHASE2

Rituximab in the Treatment of Patients With Bullous Pemphigoid

NCT00286325 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Janus Kinase Inhibition in Granuloma Annulare

NCT05650736 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

NCT00690846 ·Status: WITHDRAWN ·Phase: PHASE2

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

NCT04598477 ·Status: TERMINATED ·Phase: PHASE3

Use of Infliximab for the Treatment of Pemphigus Vulgaris

NCT00283712 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid

NCT04128176 ·Status: WITHDRAWN ·Phase: PHASE3

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

NCT02613910 ·Status: TERMINATED ·Phase: PHASE3

Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease

NCT07113743 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2

Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

NCT00134134 ·Status: COMPLETED ·Phase: PHASE1

Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

NCT05649098 ·Status: RECRUITING ·Phase: EARLY_PHASE1

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

NCT05192200 ·Status: COMPLETED ·Phase: PHASE2

A Study of PRN1008 in Patients With Pemphigus

NCT03762265 ·Status: TERMINATED ·Phase: PHASE3

A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris

NCT02704429 ·Status: COMPLETED ·Phase: PHASE2

A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris

NCT03780166 ·Status: WITHDRAWN ·Phase: PHASE2

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

NCT05681481 ·Status: TERMINATED ·Phase: PHASE3

Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid

NCT02874079 ·Status: UNKNOWN ·Phase: NA

Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency

NCT02789397 ·Status: WITHDRAWN ·Phase: PHASE2

Assessment of the 1-year Relapse Rate in Patients with Pemphigus Treated According to the Revised Pemphigus PNDS

NCT06903494 ·Status: COMPLETED